EU approval for MSD and AZ\'s Lynparza in firstline BRCAmutated advanced ovarian cancer

EU approval for MSD and AZ's Lynparza in first-line BRCA-mutated advanced ovarian cancer

06:15 EDT 18 Jun 2019 | Pharmafile

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the first-line treatment of female patients with BRCA-mutated advanced ovarian cancer.

Specifically, the authorisation covers the maintenance of FIGO Stages III and IV BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in those who are in response (complete or partial) following completion of 1st-line platinum-based chemotherapy.

EU approval for MSD and AZ\'s Lynparza in firstline BRCAmutated advanced ovarian cancer

EU approval for MSD and AZ's Lynparza in first-line BRCA-mutated advanced ovarian cancer

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the first-line treatment of female patients with BRCA-mutated advanced ovarian cancer.

More From BioPortfolio on "EU approval for MSD and AZ's Lynparza in first-line BRCA-mutated advanced ovarian cancer"